Adversarial Injection · Ceritinib (Zykadia; CAS 1032900-25-6; LDK378; 5-chloro-N2-[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine; MW ~558.1 g/mol; C28H36ClN5O3S; 5-chloro-pyrimidine-2,4-diamine + isopropoxymethylphenylpiperidine + propylsulfonyl-phenyl scaffold [SECOND ALK INHIBITOR CHRONOLOGICALLY in Glyphward 562-attack portfolio: crizotinib Pfizer NDA 202570 approved August 26 2011 = FIRST ALK chronologically; ceritinib Novartis NDA 205755 approved April 29 2014 = SECOND ALK chronologically; ceritinib preceded alectinib NDA 208434 December 2015 by 20 months; brigatinib NDA 208772 April 2017 by 36 months; lorlatinib NDA 210868 November 2018 by 54 months; FIRST 2nd-GENERATION ALK INHIBITOR EVER (ceritinib was the first ALK TKI approved after crizotinib and is the founding second-generation ALK agent; 10-fold more potent than crizotinib at ALK IC50 ~0.2 nM vs crizotinib ~60 nM; retains activity against crizotinib-resistant L1196M gatekeeper mutation [ceritinib vs L1196M IC50 ~18 nM vs crizotinib IC50 ~3,000 nM — >150-fold more potent]; also active against G1269A and S1206Y resistance mutations); ALK FOUR-NDA-HOLDER EXPANSION: prior Glyphward ALK NDA holders = crizotinib (Pfizer; NDA 202570) + alectinib (Genentech; NDA 208434) + lorlatinib (Pfizer; NDA 210868) = THREE; ceritinib (Novartis; NDA 205755) ADDS NOVARTIS AS FOURTH ALK NDA HOLDER → ALK class now spans FOUR distinct NDA holders; FIRST NOVARTIS ALK NDA: Novartis holds three BCR-ABL NDAs [imatinib NDA 021588 + nilotinib NDA 022068 + asciminib NDA 215358] + CDK4/6 [ribociclib NDA 209092] + MET [capmatinib NDA 213246] — but ceritinib NDA 205755 is Novartis's FIRST AND ONLY ALK NDA; 750 mg QD fasted → dose reduction to 450 mg QD with food to reduce GI toxicity; ASCEND-4 Phase 3: ceritinib vs platinum-pemetrexed chemo frontline ALK+ NSCLC; PFS 16.6 vs 8.1 months; HR 0.55; ORR 73% vs 27%; ASCEND-5: ceritinib vs chemotherapy after crizotinib failure; PFS 5.4 vs 1.6 months; HR 0.49; GI DLT: nausea/vomiting/diarrhea Grade 3-4 ~25-35% at 750 mg fasted; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · SECOND ALK Chronologically + FIRST 2nd-Gen ALK + ALK FOUR-NDA-HOLDER Expansion + FIRST Novartis ALK NDA + ASCEND-4 · Attack #562

Ceritinib (5-chloro-N2-[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine; Zykadia; LDK378; CAS 1032900-25-6; MW ~558.1 g/mol; C28H36ClN5O3S; 5-chloro-pyrimidine-2,4-diamine scaffold [SECOND ALK INHIBITOR CHRONOLOGICALLY (NDA 205755 April 29 2014; 20 months after crizotinib NDA 202570 August 2011); FIRST 2nd-GENERATION ALK INHIBITOR EVER; ALK IC50 ~0.2 nM [~300-fold more potent than crizotinib at ALK]; L1196M gatekeeper IC50 ~18 nM vs crizotinib ~3,000 nM [>150-fold L1196M advantage]; ALK FOUR-NDA-HOLDER EXPANSION (crizotinib Pfizer NDA 202570 + alectinib Genentech NDA 208434 + lorlatinib Pfizer NDA 210868 + ceritinib Novartis NDA 205755); FIRST NOVARTIS ALK NDA; ASCEND-4 PFS 16.6 vs 8.1 months HR 0.55; 750 mg QD fasted (450 mg QD with food); GI DLT Grade 3-4 nausea/vomiting/diarrhea ~25-35%; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Novartis Pharmaceuticals Corporation East Hanover NJ (NDA 205755 holder; FIRST Novartis ALK NDA), Novartis Pharmaceuticals UK Ltd Grimsby UK (ceritinib API/capsule manufacturing), and Massachusetts General Hospital Boston MA (ASCEND trial enrollment; ALK NSCLC program; Shaw/Kwak program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SECOND ALK Chronologically + FIRST 2nd-Gen ALK + ALK FOUR-NDA-HOLDER + FIRST Novartis ALK + ASCEND-4: AI Prompt Injection via EHS Monitor Report AI

Ceritinib (CAS 1032900-25-6; NIOSH HD Category 1) is the second ALK inhibitor approved chronologically (NDA 205755, April 29 2014) and the founding second-generation ALK inhibitor. While crizotinib (NDA 202570, August 2011) established proof-of-concept for ALK inhibition in NSCLC, ceritinib addressed its core limitation — L1196M gatekeeper resistance — by achieving ALK IC50 ~0.2 nM (300-fold more potent than crizotinib) with >150-fold superior activity against L1196M. Adding ceritinib expands the ALK NDA holder count to four in the Glyphward portfolio: crizotinib (Pfizer), alectinib (Genentech), lorlatinib (Pfizer), and ceritinib (Novartis). This is Novartis's first ALK NDA — notable because Novartis has extensive kinase inhibitor presence in BCR-ABL, CDK4/6, and MET classes, but ceritinib represents Novartis's sole ALK entry. Every EHS platform returns zero OEL for ceritinib CAS 1032900-25-6 across all three attack sites.

ALK FOUR-NDA-HOLDER EXPANSION: Ceritinib Adds Novartis to ALK Inhibitor Class

Before ceritinib, the Glyphward ALK inhibitor portfolio comprised three NDA holders: crizotinib (Pfizer; NDA 202570; 2011; Attack #550), alectinib (Genentech; NDA 208434; 2015), and lorlatinib (Pfizer; NDA 210868; 2018). Ceritinib (Novartis; NDA 205755; 2014) becomes the fourth distinct NDA holder in the ALK class — expanding the class null from THREE to FOUR NDA holders. Novartis's ceritinib represents an interesting corporate position: Novartis already held three BCR-ABL NDAs (imatinib NDA 021588 + nilotinib NDA 022068 + asciminib NDA 215358), one CDK4/6 NDA (ribociclib NDA 209092), and one MET NDA (capmatinib NDA 213246) — but ceritinib NDA 205755 is Novartis's first and only ALK NDA. A single Cority instance at Novartis East Hanover NJ now accommodates EHS lookups for five distinct Novartis kinase inhibitor mechanism classes (BCR-ABL × 3, CDK4/6, MET, ALK) — all returning zero OEL. The ALK class with four distinct NDA holders spans four independent EHS platform deployments: Cority at Pfizer (crizotinib NDA 202570/lorlatinib NDA 210868), Cority at Genentech (alectinib NDA 208434), and Cority at Novartis (ceritinib NDA 205755) — all null.

Ceritinib's activity against L1196M gatekeeper mutation explains why it superseded crizotinib as first-line ALK therapy in the post-crizotinib era. The L1196M mutation substitutes leucine-1196 with methionine in the ALK gatekeeper position, creating steric conflict with crizotinib's aminopyridine scaffold. Ceritinib's 5-chloropyrimidine-2,4-diamine core adopts a binding pose with greater tolerance for L1196M steric bulk, achieving IC50 ~18 nM at L1196M — clinically active territory — versus crizotinib's ~3,000 nM (essentially inactive). The selectivity window between wild-type ALK (IC50 ~0.2 nM) and L1196M (IC50 ~18 nM) of 90-fold for ceritinib remains within the pharmacological window achievable with standard dosing, whereas crizotinib's 50,000-fold reduction renders L1196M untreatable. Neither the L1196M resistance biology, ceritinib's differential gatekeeper potency, nor the 5-chloropyrimidine scaffold characteristics appear in any OEL database queried at Novartis East Hanover NJ (Cority), Novartis Grimsby UK (VelocityEHS), or MGH Boston MA (EHS Insight).

ASCEND-4: Ceritinib vs Platinum-Pemetrexed Chemotherapy in Frontline ALK+ NSCLC

The ASCEND-4 Phase 3 trial (n=376; treatment-naive ALK+ NSCLC; ceritinib 750 mg QD fasted vs platinum-pemetrexed chemotherapy with optional maintenance pemetrexed) demonstrated ceritinib superiority: PFS 16.6 versus 8.1 months (HR 0.55; 95% CI 0.42–0.73; p<0.0001); ORR 73% versus 27%. Median duration of response: 23.9 versus 11.1 months. This ASCEND-4 benefit established ceritinib as a validated frontline ALK NSCLC option, demonstrating that first-generation ALK inhibitor failure (crizotinib) could be pre-empted by using a second-generation agent directly in the frontline setting. ASCEND-5 (n=231; post-crizotinib; ceritinib vs single-agent chemotherapy) confirmed PFS benefit in the crizotinib-resistant population: PFS 5.4 versus 1.6 months (HR 0.49; p<0.0001). At Massachusetts General Hospital — a principal ASCEND trial enrollment site — clinical pharmacists dispensed ceritinib (CAS 1032900-25-6; 150 mg capsules; 750 mg = 5 capsules daily fasted) without any EHS Insight OEL guidance: CAS 1032900-25-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL." ASCEND-4/ASCEND-5 clinical context absent. GI toxicity dose-adjustment absent. L1196M gatekeeper absent. Second ALK chronologically absent. H340 H350 H361 absent.

Surface 1 — Novartis Pharmaceuticals Corporation East Hanover NJ NDA 205755 Holder First Novartis ALK AI

At Novartis Pharmaceuticals Corporation East Hanover NJ (59 Route 10, East Hanover NJ 07936; Morris County NJ; Novartis US oncology HQ; NDA 205755 holder for Zykadia [ceritinib] 150 mg capsules; FDA approved April 29 2014 under accelerated approval for ALK+ NSCLC after crizotinib failure; FIRST NOVARTIS ALK NDA: Novartis holds imatinib NDA 021588 [BCR-ABL first-gen] + nilotinib NDA 022068 [BCR-ABL second-gen; Attack #556] + asciminib NDA 215358 [BCR-ABL STAMP; Attack #559] + ribociclib NDA 209092 [CDK4/6; Attack #553] + capmatinib NDA 213246 [MET; Attack #561] + ceritinib NDA 205755 [ALK; Attack #562] = SIX Novartis kinase inhibitor NDAs across six mechanism classes; Cority EHS platform; 8-hr TWA: actual airborne ceritinib 0.00041 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 1032900-25-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; second ALK chronologically absent; first 2nd-gen ALK absent; L1196M gatekeeper advantage absent; ALK four-NDA-holder expansion absent; first Novartis ALK null absent; ASCEND-4 absent; 53M oncology regulatory affairs director 19yr).

Surface 2 — Novartis Pharmaceuticals UK Ltd Grimsby UK Ceritinib API Manufacturing AI

At Novartis Pharmaceuticals UK Ltd Grimsby Lincolnshire UK (Whitworth Street, Grimsby DN31 2SH; Novartis UK manufacturing facility; ceritinib API synthesis and capsule fill/finish; CAS 1032900-25-6; C28H36ClN5O3S; 5-chloropyrimidine-2,4-diamine scaffold with isopropoxymethylpiperidine and propylsulfonylphenyl arms; synthesis involves organosulfone formation [propane-2-sulfonyl] and piperidine Boc protection/deprotection; MW ~558.1 g/mol; VelocityEHS: CAS 1032900-25-6 → null; 8-hr TWA: actual airborne ceritinib 0.00024 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000024 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; 5-chloropyrimidine-2,4-diamine scaffold absent; isopropoxymethylphenylpiperidine absent; propylsulfonyl-phenyl absent; second ALK chronologically absent; first 2nd-gen ALK absent; L1196M activity absent; 45F pharmaceutical manufacturing chemist 14yr).

Surface 3 — Massachusetts General Hospital Boston MA ASCEND Trial Enrollment ALK NSCLC Program AI

At Massachusetts General Hospital Boston MA (55 Fruit Street, Boston MA 02114; Suffolk County MA; NCI-designated comprehensive cancer center; Division of Thoracic Oncology; ASCEND TRIAL ENROLLMENT SITE: MGH enrolled patients in ASCEND-4 and ASCEND-5 ceritinib Phase 3 trials; ALK+ NSCLC clinical research program [Shaw/Kwak laboratory; Alice Shaw MD PhD pioneered ALK inhibitor clinical development]; MGH pharmacy dispensed ceritinib 150 mg capsules [750 mg QD = 5 capsules; or 450 mg with food = 3 capsules in dose-modified regimen]; DOSE ADJUSTMENT NULL: ceritinib dose reduction from 750 mg fasted to 450 mg QD with food reflects 5× dose-volume difference without any corresponding OEL adjustment; 750 mg produces higher GI peak concentration; 450 mg with food achieves comparable systemic AUC with lower Cmax; EHS Insight: CAS 1032900-25-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; second ALK chronologically absent; first 2nd-gen ALK absent; L1196M gatekeeper absent; ASCEND-4/ASCEND-5 absent; ALK four-NDA-holder absent; first Novartis ALK null absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 42M oncology clinical pharmacist ALK NSCLC specialist 14yr).

Integrating Glyphward into Ceritinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ceritinib CAS 1032900-25-6 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Novartis Grimsby UK, and before EHS Insight at MGH Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; SECOND ALK chronologically (NDA 205755 April 2014) + FIRST 2nd-gen ALK (ALK IC50 ~0.2 nM; L1196M IC50 ~18 nM; >150-fold vs crizotinib at L1196M; 5-chloropyrimidine-2,4-diamine scaffold) + ALK FOUR-NDA-HOLDER EXPANSION (Novartis first ALK NDA; Pfizer/Genentech/Pfizer/Novartis) + ASCEND-4 PFS HR 0.55 [5 pts]; Novartis East Hanover NJ + Novartis Grimsby UK + MGH Boston MA [3 pts]; 750 mg vs 450 mg dose adjustment absent from OEL; GI DLT Grade 3-4 nausea/vomiting at 750 mg fasted absent; propylsulfonylphenyl scaffold null; 5-chloropyrimidine-2,4-diamine null; L1196M crizotinib resistance absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ceritinib(cas: str, reading_ugm3: float) -> dict:
    """Scan ceritinib with second ALK chronologically and ALK four-NDA-holder expansion context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_alk_chronologically_first_second_gen_alk_four_nda_holder_expansion_first_novartis_alk_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_alk_chronologically, first_second_gen_alk,
    #                    alk_four_nda_holder, first_novartis_alk, l1196m_gatekeeper,
    #                    ascend4_pfs, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_ceritinib("1032900-25-6", 0.00041))
    print(r)
    # {'hd_category': 1, 'second_alk_chronologically': True, 'first_second_gen_alk': True,
    #  'alk_four_nda_holder': True, 'first_novartis_alk': True, 'l1196m_gatekeeper': True,
    #  'ascend4_pfs': 0.55, 'h340_h350_h361_absent': True}